Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

IBRX

IBRX News

Newswire

06:15

FDA Meeting for ImmunityBio's Anktiva Drug Scuttled Amid Internal Opposition and Political Pressure

05:03

ImmunityBio Q3 Earnings Beat Expectations, Revenue Up 425% YoY.

05:44

ImmunityBio Inc. (IBRX) - A Biotech Stock with High Upside Potential

16:14

ImmunityBio shares surge 10.80% after hours on FDA designations, positive trials, and 467% ANKTIVA sales growth.

10:01

ImmunityBio shares surge 11.03% intraday on improved Q3 revenue and narrowed net loss from Anktiva demand.

View More

About IBRX

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More